Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein

US7097965B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Kurt Klimpel · Gaithersburg, US
• Theresa Goletz · Kensington, US
• Naveen Arora · Hyderabad, IN
• Stephen H. Leppla · Bethesda, US
• Jay A. Berzofsky · Bethesda, US

Key dates

• Filing date: May 27, 2003
• Grant date: Aug 29, 2006
• Expiry date: Jul 28, 2024

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S530/825
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a vaccine for inducing an immune response in mammal to a specific antigen, where the vaccine comprises a unit dose of a binary toxin protective antigen and the antigen, which is bound to a binary toxin protective antigen binding protein. In one embodiment the vaccine is comprised of an anthrax protective antigen and the antigen bound to anthrax protective antigen binding protein. The present invention also provides a method of immunizing a mammal against an antigen using the vaccine, and a method of inducing antigen-presenting mammalian cells to present specific antigens via the MHC class I processing pathway.